Compounds and methods for kinase modulation, and indications therefor
US-2016176865-A1 · Jun 23, 2016 · US
US10647716B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10647716-B2 |
| Application number | US-201916441610-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 14, 2019 |
| Priority date | Sep 21, 2015 |
| Publication date | May 12, 2020 |
| Grant date | May 12, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.
Opening claim text (preview).
What is claimed is: 1. A process of making compound 13: said process comprising contacting compound 12: with potassium tert-butoxide and iodomethane under conditions sufficient to form compound 13. 2. A process of making compound P-002: said process comprising contacting compound 13: with compound 13b: in the presence of [1,1′-Bis(diphenyl-phosphino)ferrocene]dichloropalladium(II) under conditions sufficient to form compound P-002. 3. A process of making a compound P-001: said process comprising contacting compound P-002: with lithium hydroxide under conditions sufficient to form compound P-001. 4. A compound of formula: 5. A method for treating acute myeloid leukemia comprising administering to a subject in need thereof an effective amount of a compound of formula: or a pharmaceutically acceptable salt thereof, and azacitidine. 6. A method for treating ovarian cancer comprising administering to a subject in need thereof an effective amount of a compound of formula: or a pharmaceutically acceptable salt thereof, and carboplatin.
Drugs for disorders of the cardiovascular system · CPC title
of urine or of the urinary tract, e.g. urine acidifiers · CPC title
for myasthenia gravis · CPC title
Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.